Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten analysts that are covering the stock, MarketBeat.com reports. Two research...